Fidaxomicin
Top View
- Updated Management Guidelines for Clostridioides Difficile in Paediatrics
- Pharmacy News 1Q11
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Dificlir, INN-Fidaxomicin
- TREATMENT of RECURRENT Clostridioides Difficile INFECTION
- Estonian Statistics on Medicines 2017 1/42
- PEDIATRIC Tier I
- A Review of US Food and Drug Administration–Approved Antibiotics
- Recommendations for Anti-Microbial Use for Secondary Infections in Patients with COVID-19 Rapid Review
- Stoplight-Guidelines-Antimicrobial-Use
- Fidaxomicin Use for Clostridium Difficile Infection Probably Decreases the Effect of Coumadin® in Elderly
- Antimicrobial Guide
- Assessment and Management of Clostridioides Difficile Infections (CDI)
- Fidaxomicin Jams Mycobacterium Tuberculosis RNA Polymerase Motions Needed for Initiation Via Rbpa Contacts
- Dificlir, Fidaxomicin
- Architectures of US FDA Approved Pharmaceuticals Containing
- Drug Pipeline MONTHLY UPDATE
- Clostridium Difficile Infection (CDI) Treatment Algorithm—Initial Episode